Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
暂无分享，去创建一个
C. Porta | R. Motzer | T. Choueiri | D. Cella | A. Kapoor | B. Alekseev | S. Rha | R. Perini | M. Eto | Sung-Hoo Hong | M. Méndez-Vidal | J. Goh | L. Bennett | C. He | K. Mody | T. Saretsky | Jinyi Wang | Jie Janice Pan | J. Pan